New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More
Broadly Engaged Team Science Comes to Life in a Design Lab
The objective of broadly engaged team science is to bring a diverse group of stakeholders into a project early and continue to include their expertise throughout to inform and propel … Read More
Precision for Whom? Partnering with patients to ensure that Precision Medicine targets what matters
Despite decades of growth and adaptation in patient engagement, knowing or being able to find guidance for whichmodel or approach will be most impactful in which healthcare or research context … Read More
The resource navigation challenges for patients and caregivers
Share the researchWhile the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers are directly affected by many different elements … Read More
Downstream Innovation Part II
December 2019 marked the transition from the LEAPS two-year design and feasibility assessment phase to the rollout of the rheumatoid arthritis in Massachusetts (RA MA) Pilot. Some important themes surrounding … Read More
Downstream Innovation Part I
There is a growing recognition of the importance of augmenting product- focused learning with disease-focused learning, incorporating the value of advances in real-world evidence (RWE). In LEAPS, we aim to … Read More
Advancing Healthcare through Innovation and Collaboration
NEWDIGS is an exciting and innovative approach to developing solutions for systemwide impediments to biomedical innovation and patient care. The noncompetitive, collaborative environment encourages novel and fresh ideas and interactions to … Read More
Transforming Real-World Evidence in Biomedical Innovation: Advancing the Design of Collaborative Disease-Focused Learning Ecosystems
The LEAPS methodology begins by answering two structured questions – WHAT evidence to produce, and HOW to produce it, as outlined in this two-part Research Brief series: • Part I: … Read More
Leaping Together Toward Sustainable, Patient‐Centered Innovation: The Value of a Multistakeholder Safe Haven for Accelerating System Change
Clinical Pharmacology & Therapeutics, November 2, 2018Gigi Hirsch Successfully delivering on the promise of emerging science in a world of value-driven healthcare requires that we fundamentally reengineer biomedical innovation processes … Read More
Designing financial solutions to ensure affordable access to cures
The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved … Read More
- Page 1 of 2
- 1
- 2